Trial Profile
Randomized phase II study comparing pegylated interferon alpha-2b combined with intra-arterial 5-fluorouracil and sorafenib alone for advanced hepatocellular carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Peginterferon alfa-2b (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Therapeutic Use
- 22 Aug 2012 New trial record
- 01 Jan 2009 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.